List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Degenerative Disc Disease - Overview
Degenerative Disc Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Degenerative Disc Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Degenerative Disc Disease - Companies Involved in Therapeutics Development
Amplicore Inc
AnGes Inc
Angitia Biopharmaceuticals
Bone Therapeutics SA
CHA Biotech Co Ltd
DiscGenics Inc
FibroGenesis LLC
Genequine Biotherapeutics GmbH
Histogen Inc
Kolon TissueGene Inc
Locate Bio Ltd
Notogen Inc
Rudacure Co Ltd
Spine BioPharma LLC
Stayble Therapeutics AB
Techfields Pharma Co Ltd
U.S. Stem Cell Inc
Xalud Therapeutics Inc
Degenerative Disc Disease - Drug Profiles
AdipoCell - Drug Profile
Product Description
Mechanism Of Action
AGA-111 - Drug Profile
Product Description
Mechanism Of Action
ALLOB - Drug Profile
Product Description
Mechanism Of Action
History of Events
AM-2101 - Drug Profile
Product Description
Mechanism Of Action
AMG-0101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AMG-0103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CBAC-01 - Drug Profile
Product Description
Mechanism Of Action
CBAC-03 - Drug Profile
Product Description
Mechanism Of Action
Cell Therapy for Degenerative Disc Disease and Spinal Cord Injury - Drug Profile
Product Description
Mechanism Of Action
CybroCell - Drug Profile
Product Description
Mechanism Of Action
GQ-401 - Drug Profile
Product Description
Mechanism Of Action
HST-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LB-002 - Drug Profile
Product Description
Mechanism Of Action
NTG-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
rebonuputemcel - Drug Profile
Product Description
Mechanism Of Action
History of Events
Remedisc - Drug Profile
Product Description
Mechanism Of Action
History of Events
STA-363 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy 1 for Degenerative Disc Disease - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Degenerative Disc Disease - Drug Profile
Product Description
Mechanism Of Action
TG-D - Drug Profile
Product Description
Mechanism Of Action
X-0002 - Drug Profile
Product Description
Mechanism Of Action
XT-150 - Drug Profile
Product Description
Mechanism Of Action
Degenerative Disc Disease - Dormant Projects
Degenerative Disc Disease - Product Development Milestones
Featured News & Press Releases
May 14, 2020: Histogen publishes preclinical data on its HST 004 spinal disc program
Nov 14, 2018: Therapeutic potential of NTG-101, a single dose injectable treatment for Degenerative Disc Disease, demonstrated in preclinical large animal study published in Nature Publishing Group's "Scientific Reports"
Mar 20, 2018: USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas
Feb 28, 2018: USRM Chief Science Officer to Present at Academy of Regenerative Practices Conference
Jan 15, 2018: USRM Reaches Key Sales Milestone of Proprietary Adipocell Product
Nov 28, 2017: Degenerative Disc Patients Significantly Improve With USRM's Adipocell
Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study
Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study
Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells' Conference
Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial
Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease
Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion
Mar 26, 2014: Bioheart Announces Clinical Study for Degenerative Disc Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Degenerative Disc Disease, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Degenerative Disc Disease - Pipeline by Amplicore Inc, 2022
Degenerative Disc Disease - Pipeline by AnGes Inc, 2022
Degenerative Disc Disease - Pipeline by Angitia Biopharmaceuticals, 2022
Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, 2022
Degenerative Disc Disease - Pipeline by CHA Biotech Co Ltd, 2022
Degenerative Disc Disease - Pipeline by DiscGenics Inc, 2022
Degenerative Disc Disease - Pipeline by FibroGenesis LLC, 2022
Degenerative Disc Disease - Pipeline by Genequine Biotherapeutics GmbH, 2022
Degenerative Disc Disease - Pipeline by Histogen Inc, 2022
Degenerative Disc Disease - Pipeline by Kolon TissueGene Inc, 2022
Degenerative Disc Disease - Pipeline by Locate Bio Ltd, 2022
Degenerative Disc Disease - Pipeline by Notogen Inc, 2022
Degenerative Disc Disease - Pipeline by Rudacure Co Ltd, 2022
Degenerative Disc Disease - Pipeline by Spine BioPharma LLC, 2022
Degenerative Disc Disease - Pipeline by Stayble Therapeutics AB, 2022
Degenerative Disc Disease - Pipeline by Techfields Pharma Co Ltd, 2022
Degenerative Disc Disease - Pipeline by U.S. Stem Cell Inc, 2022
Degenerative Disc Disease - Pipeline by Xalud Therapeutics Inc, 2022
Degenerative Disc Disease - Dormant Projects, 2022

List of Figures
Number of Products under Development for Degenerative Disc Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Companies Mentioned
• Amplicore Inc
• AnGes Inc
• Angitia Biopharmaceuticals
• Bone Therapeutics SA
• CHA Biotech Co Ltd
• DiscGenics Inc
• FibroGenesis LLC
• Genequine Biotherapeutics GmbH
• Histogen Inc
• Kolon TissueGene Inc
• Locate Bio Ltd
• Notogen Inc
• Rudacure Co Ltd
• Spine BioPharma LLC
• Stayble Therapeutics AB
• Techfields Pharma Co Ltd
• U.S. Stem Cell Inc
• Xalud Therapeutics Inc